Novel Drug Targeting of the Circadian Factor REV-ERB Limits Infarct Expansion and Remodelling After Myocardial Ischemia/Reperfusion
Novel Drug Targeting of the Circadian Factor REV-ERB Limits Infarct Expansion and Remodelling After Myocardial Ischemia/Reperfusion
批准号:
369619
负责人:
Martino Tami
金额:
$47.09万
依托单位:
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2017
资助国家:
加拿大
项目状态:
已结题
起止时间:
2017-09-01 至 2022-09-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Ischemic heart disease leading to myocardial infarction (MI, heart attack) is a leading cause of death worldwide. Although many patients reach hospitals in a timely manner and undergo post-ischemia reperfusion (mI/R), this triggers a profound inflammatory
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pre-Clinical Translation of Circadian Biology to Benefit Treatment of Heart Disease
-
批准号:354400
-
项目类别:Operating Grants
-
资助金额:$68.27万
-
财政年份:2016
-
负责人:Martino Tami
-
依托单位:
Circadian Control of Cardiac Remodeling
-
批准号:238301
-
项目类别:Operating Grants
-
资助金额:$24.44万
-
财政年份:2011
-
负责人:Martino Tami
-
依托单位:
海外基金